FDA denies Ardelyx’s appeal against kidney drug rejection, hammering another nail in tenapanor’s coffin

The FDA has deflated Ardelyx's attempt to recover quickly from a complete response letter. With Ardelyx looking to sidestep a request for another trial, the FDA held its ground and denied the appeal—leaving the biotech looking to a Hail Mary pass to overturn the decision.